{"generic":"Diphtheria, Tetanus, Pertussis, Poliovirus, and Hib Vaccine","drugs":["Diphtheria, Tetanus, Pertussis, Poliovirus, and Hib Vaccine","Pentacel"],"mono":{"0":{"id":"930622-s-0","title":"Generic Names","mono":"Diphtheria, Tetanus, Pertussis, Poliovirus, and Hib Vaccine"},"1":{"id":"930622-s-1","title":"Dosing and Indications","sub":{"1":{"id":"930622-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in children 5 years of age or older<\/li><li><b>Diphtheria, pertussis and tetanus triple and polio vaccination - Hemophilus influenzae type B infection, Invasive; Prophylaxis:<\/b> (6 weeks to less than 5 years of age) primary series, 0.5 mL IM x 4 doses given at 2, 4, 6, and 15 to 18 months of age<\/li><li><b>Diphtheria, pertussis and tetanus triple and polio vaccination - Hemophilus influenzae type B infection, Invasive; Prophylaxis:<\/b> upon completion of the 4-dose series of Pentacel(R), administer a fifth dose of diphtheria and tetanus toxoids, adsorbed, and acellular pertussis vaccine (DTaP) at 4 to 6 years of age; use of Daptacel(R) for DTaP is recommended due to similarity of pertussis antigens<\/li><li><b>Diphtheria, pertussis and tetanus triple and polio vaccination - Hemophilus influenzae type B infection, Invasive; Prophylaxis:<\/b> administer with an appropriate antipyretic and for 24 hours following vaccination in patients with a history of previous seizures<\/li><li><b>Diphtheria, pertussis and tetanus triple and polio vaccination - Hemophilus influenzae type B infection, Invasive; Prophylaxis:<\/b> the same brand of diphtheria and tetanus toxoids, adsorbed, and acellular pertussis vaccine (DTaP) vaccine should be used for all doses in the vaccination series, whenever feasible<\/li><\/ul>"},"3":{"id":"930622-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Diphtheria, pertussis and tetanus triple and polio vaccination - Hemophilus influenzae type B infection, Invasive; Prophylaxis<br\/>"}}},"3":{"id":"930622-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930622-s-3-9","title":"Contraindications","mono":"<ul><li>age less than 6 weeks<\/li><li>encephalopathy (eg, coma, decreased levels of consciousness, prolonged seizures) within 7 days of a previous dose of pertussis not attributable to other causes<\/li><li>progressive neurologic disorder (eg, infantile spasms, uncontrolled epilepsy, progressive encephalopathy); contraindicated until neurologic status is stabilized<\/li><li>severe allergic reaction (anaphylaxis) to previous dose of vaccine combination, any vaccine component, or product ingredient<\/li><\/ul>"},{"id":"930622-s-3-10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>anaphylactic or acute hypersensitivity reactions may occur<\/li><li>brachial neuritis may occur with administration of tetanus toxoid-containing vaccination<\/li><li>collapse or shock-like state (hypotonic-hyporesponsive episode) occurring within 48 hours of any pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>crying, persistent, inconsolable; duration of at least 3 hours occurring within 48 hours of any pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>fever, (105 degrees F or 40.5 degrees C or higher) occurring within 48 hours of any pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>Guillain-Barre syndrome occurring within 6 weeks of any tetanus toxoid-containing vaccine; increased risk of recurrence; evaluate benefit\/risk prior to administration<\/li><li>hypersensitivity reaction, arthus-type, after a previous tetanus-toxoid-containing vaccine; defer vaccination until at least 10 years since last tetanus-toxoid-containing vaccine<\/li><li>lack of immune response to vaccine may occur in some patients, especially if immunosuppressed<\/li><li>pregnancy; can be administered if there is a risk for exposure to wild-type poliovirus infection<\/li><li>premature infants; apnea has been observed following intramuscular vaccination; consider medical status and risk\/benefits prior to administration<\/li><li>revaccination in patients with unknown vaccination history; after the fourth and fifth DTaP dose an increased rate of adverse events may occur; serologic testing may be indicated<\/li><li>seizure history; an antipyretic medication, given at the time of vaccination and for 24 hours post-vaccination, may reduce risk of post-vaccination fever<\/li><li>seizure, with or without fever, occurring within 3 days of any pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>report adverse events to VAERS 1-800-822-7967, or http:\/\/www.vaers.hhs.gov<\/li><\/ul>"},{"id":"930622-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930622-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930622-s-4","title":"Drug Interactions","sub":{"1":{"id":"930622-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"},"2":{"id":"930622-s-4-15","title":"Moderate","mono":"<ul><li>Chloramphenicol (probable)<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent (established)<\/li><\/ul>"}}},"5":{"id":"930622-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (7.1% to 17.3%), Injection site pain (39.2% to 56.1%), Swelling at injection site (5% to 9.7%)<\/li><li><b>Neurologic:<\/b>Lethargy (24.1% to 45.8%)<\/li><li><b>Psychiatric:<\/b>Crying, inconsolable (35.9% to 59.3%), Irritability (53.5% to 76.9%)<\/li><li><b>Other:<\/b>Fever (5.8% to 16.3%), Increase in circumference, arm (33.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Collapse, hypotonic-hyporesponsive episode<\/li><li><b>Dermatologic:<\/b>Injection site reaction, severe<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"930622-s-6","title":"Drug Name Info","sub":{"0":{"id":"930622-s-6-17","title":"US Trade Names","mono":"Pentacel<br\/>"},"2":{"id":"930622-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"930622-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930622-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930622-s-7","title":"Mechanism Of Action","mono":"<ul><li>Diphtheria: Following IM injection, diphtheria toxoid induces the formation of neutralizing antibodies to diphtheria toxin.<\/li><li>Tetanus: Following IM injection, tetanus toxoid induces the formation of neutralizing antibodies to tetanus toxin.<\/li><li>Pertussis: Following IM injection, acellular pertussis vaccine induces the formation of several antibodies thought to be clinically protective. The levels of antibody necessary for protection have not been determined.<\/li><li>Inactivated Poliovirus Vaccine (IPV): Following IM injection, IPV induces the production of neutralizing antibodies against each poliovirus serotype correlating with protection against poliomyelitis.<\/li><\/ul>"},"9":{"id":"930622-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>For IM use only; do not administer IV or subQ<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>add the component of diphtheria and tetanus toxoid, acellular pertussis, and inactivated poliovirus to the Haemophilus b conjugate component<\/li><li>combined suspension will be cloudy, white to off-white color with a yellow tinge<\/li><li>administer immediately upon reconstitution<\/li><li>in infants younger than 1 year, anterolateral aspect of thigh is preferred site of injection; deltoid muscle may be used in older children<\/li><li>do not inject in gluteal area(s) or areas where there may be a major nerve trunk<\/li><li>use separate syringes and site when administering concomitantly with other vaccines<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930622-s-10","title":"Monitoring","mono":"signs\/symptoms of hypersensitivity to acellular pertussis component of vaccine <br\/>"},"11":{"id":"930622-s-11","title":"How Supplied","mono":"<b>Pentacel<\/b><br\/>KIT: (Diphtheria Toxoid, Adsorbed - Pertussis Vaccine, Acellular - Poliovirus Vaccine, Inactivated - Tetanus Toxoid;Haemophilus B Conjugate VaccineDiphtheria Toxoid, Adsorbed - Pertussis Vaccine, Acellular - Poliovirus Vaccine, Inactivated - Tetanus Toxoid;Haemophilus B Conjugate Vaccine) 15 Lf U\/0.5 ML,10 MCG,48 MCG\/0.5 ML,80 D Antigen U\/0.5 ML,5 Lf U\/0.5 ML<br\/>"},"13":{"id":"930622-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause injection site reactions, decreased activity, lethargy, fussiness, irritability, dehydration, gastroenteritis, bronchiolitis, asthma, and pneumonia.<\/li><li>Instruct parent or caregiver to report a temperature of 40.5 degrees Celsius (105 degrees Fahrenheit) or higher; persistent, inconsolable crying lasting 3 hours or more; or collapse or a shock-like state (hypotonic, hyporesponsive) within 48 hours of injection.<\/li><li>Instruct parent or caregiver to report a seizure with or without fever that occurs within 3 days of injection.<\/li><li>Inform caregiver of the importance of the child receiving the entire series of vaccinations in the absence of contraindications. If a dose is missed, another appointment should be scheduled as soon as possible.<\/li><\/ul>"}}}